Tower Research Capital LLC (Trc) Cingulate Inc. Transaction History

Tower Research Capital LLC (Trc)

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.52 - $0.98 $11 - $22	-23 Reduced 0.28%	8,232 $5,000
Q2 2023 Aug 14, 2023	SELL	$0.84 - $1.12 $2,184 - $2,913	-2,601 Reduced 23.96%	8,255 $7,000
Q1 2023 May 09, 2023	BUY	$0.91 - $1.85 $1,586 - $3,224	1,743 Added 19.13%	10,856 $11,000
Q4 2022 Feb 10, 2023	SELL	$0.69 - $328.8 $1,280 - $610,252	-1,856 Reduced 16.92%	9,113 $9,000
Q3 2022 Nov 10, 2022	BUY	$0.26 - $420.0 $1,913 - $3.09 Million	7,361 Added 204.02%	10,969 $12,000
Q2 2022 Aug 15, 2022	BUY	$259.2 - $453.6 $426,902 - $747,079	1,647 Added 83.99%	3,608 $5,000
Q1 2022 May 12, 2022	BUY	$278.4 - $698.4 $545,942 - $1.37 Million	1,961 New	1,961 $4,000

Ticker CING
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,309,400
Market Cap $42.2M
Description
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-de...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.